Abstract
Mycophenolate mofetil (MMF) has recently been introduced as an immunosuppressive agent for the treatment of glomerulonephritis with systemic lupus erythematosus (SLE) and the data have been encouraging. However, response to MMF treatment appears to differ ethnically. Therefore, we determined efficacy and safety of low-dose MMF for Taiwanese patients with lupus nephritis. We studied 36 lupus nephritis patients who were treated with MMF. The dose started at 0.5 g/day and we collected the data from patients who received up to 1 g/day MMF. Outcome measures were 24 h for proteinuria, serum creatinine, C3/C4 levels, and anti-dsDNA titers collected at the baseline and at 3-month treatment intervals. Daily urinary protein significantly decreased from 6.15 ± 4.28 g to 2.69 ± 2.36 g at the last visit (P < 0.01) in spite of the significant absence of changes in serum creatinine levels. The response rate was 65.7% including five (14.3%) cases of complete remission and 18 (51.4%) cases of partial remission. The concomitant oral prednisolone dose decreased significantly from 20.07 ± 11.78 mg/day to 13.93 ± 6.79 mg/day at 6 months (P < 0.01). The level of C3 increased significantly from 59.46 ± 32.73 to 71.99 ± 25.81 (P < 0.01) and the anti-dsDNA antibody titer decreased from 161.71 ± 221.42 to 46.57 ± 117.47 (P < 0.01). No severe adverse effects were observed in the study. Low-dose MMF (0.5 to 1 g/day) combined with glucocorticoids appears to be a safe and effective therapy for lupus nephritis in Taiwanese patients. Our results suggest that lupus nephritis in Oriental patients might respond to lower doses of MMF than Caucasians.
Similar content being viewed by others
References
Gladman DD, Urowitz MB (2002) Prognosis, mortality and morbidity in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1255–1273
Yee CS, Gordon C, Dostal C et al (2004) EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63:525–529
Falk RJ (2000) Treatment of lupus nephritis—a work in progress. N Engl J Med 343:1182–1183
Gourley MF, Austin HA III, Scott D et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 125:549–557
Korbet SM, Lewis EJ, Schwartz MM et al (2000) Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35:904–914
Mok CC, Yee KY, Sydney Tang, Leung CY et al (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559–2568
Ioannidis JPA, Boki KA, Katsorida EM et al (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258–264
Austin H, Klippel J, Balow J et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619
Valeri A, Radhakrishnan J, Estes D et al (1994) Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 42:71–78
Boumpas DT, Austin HA III, vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745
Eugui EM, Allison AC (1993) Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 685:309–329
Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85–118
Borba EF, Guedes LK, Christmann RB et al (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 26:1078–1083
Chan TM, Li FK, Tang CSO et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162
Chan TM, Tse KC, Tang CSO, Mok MY et al (2005) Hong Kong Nephrology Study G. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076–1084
Dooley MA, Cosio FG, Nachman PH et al (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10:833–839
Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208
Neylan JF (1997) Immunosuppressive therapy in high-risk trasplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 64:1277–1282
Dooley MA, Hogan S, Jennette C et al (1997) Cyclophosphamide therapy for lupus nephritis: poor renal suvival in black americans. Kidney Int 51:1188–1195
Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250
Ginzler EM, Aranow C (2005) Mycophenolate mofetil in lupus nephritis. Lupus 14:59–64
Elyan M, Ballou S (2009) The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Clin Rheumatol
Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736
Ginzler EM, Dooley MA, Aranow C (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228
Cross J, Dwomoa A, Andrews P et al (2005) Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 100:c92–100
Karim MY, Alba P, Cuadrado MJ et al (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41:876–882
Denton MD, Galvanek EG, Singh A, Sayegh MH (2001) Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. American Journal of Transplantation 1:288–292
Chan TM, Li FK, Tang CS, Wong RW et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162
Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112
Zhu B, Chen N, Lin Y et al (2007) Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22:1933–1942
Bijl M, Horst G, Bootsma H et al (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62:534–539
Kingdon EJ, McLean AG, Psimenou E et al (2001) The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10:606–611
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weng, MY., Weng, CT. & Liu, MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 29, 771–775 (2010). https://doi.org/10.1007/s10067-010-1403-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1403-9